Maximizing the potential of bevacizumab in cancer treatment
Maximizing the potential of bevacizumab in cancer treatment
复制标题
DOI：
10.1634/theoncologist.9-suppl_1-36
复制
发表时间：
2004-01-01
期刊：
影响因子：
5.8
通讯作者：
Dickler, MN
中科院分区：
文献类型：
--
作者：
Bergsland, E;Dickler, MN
用贝伐单抗（Avestin（TM）; Genentech，Inc.;南旧金山弗朗西斯科，加利福尼亚州）在一系列实体瘤患者的临床试验中;然而，为了最大限度地发挥这种药物的潜力，需要进一步研究来澄清一些重要问题。这些包括优化贝伐单抗剂量和给药方案，这种药物与其他治疗方式（如化疗和放疗）联合使用的潜在价值，毒性管理以及选择最有可能从治疗中获益的患者。最近两项III期试验的有趣结果强调了更好地理解将贝伐单抗纳入临床实践的最佳方法的必要性。最终，最大限度地发挥这种药物的潜在价值可能需要更彻底地了解贝伐单抗的作用机制和介导耐药性的途径。
Promising results have been obtained with bevacizumab (Avestin(TM); Genentech, Inc.; South San Francisco, CA) in clinical trials in patients with a range of solid tumors; however, to maximize the potential of this agent, further research is needed to clarify a number of important issues. These include the optimization of bevacizumab dosage and schedule of administration, the potential value of this agent in combination with other treatment modalities like chemotherapy and radiation, the management of toxicities, and the selection of patients most likely to benefit from treatment. Intriguing results from two recent phase III trials highlight the need for a better understanding of the best ways to incorporate bevacizumab into clinical practice. Ultimately, maximizing the potential value of this agent may require a more thorough understanding of bevacizumab's mechanism of action and the pathways mediating resistance.